LESCOL
LOE ApproachingNDAORALCAPSULE
Approved
Dec 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LESCOL by Novartis is hmg-coa reductase, the rate limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) to mevalonate, a precursor of cholesterol. First approved in 1993.
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LESCOL (fluvastatin) is an oral HMG-CoA reductase inhibitor (statin) approved in 1993 for cholesterol management. It works by inhibiting the rate-limiting enzyme in cholesterol synthesis, reducing LDL-C and triglycerides. The drug is indicated for patients requiring lipid-lowering therapy to reduce cardiovascular risk.
LOE Approaching
Product is in terminal lifecycle stage with minimal commercial expansion; brand teams likely focused on managed decline and cost containment rather than growth initiatives.
Mechanism of Action
HMG-CoA reductase, the rate limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate, a precursor of cholesterol.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LESCOL offers limited career growth opportunity given the product's late-stage lifecycle and shrinking market presence. Professionals may gain experience in managed decline strategies and cost management, but face constrained mobility and resource allocation.
Brand ManagerField Sales Representative
Worked on LESCOL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.